TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Na
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering

Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotech company developing molecular glue degrader medicines, announced pricing of an underwritten public offering of 11.125 million shares at $24.00 per share and 1.375 million pre-funded warrants, expected to raise approximately $300 million gross proceeds. The offering is expected to close on January 12, 2026.

Insights
GLUE   positive

The company successfully priced a $300 million public offering, demonstrating strong investor confidence and providing significant capital to fund its clinical development pipeline. This capital raise enables advancement of their three clinical programs and supports their position as a clinical-stage biotech with leading MGD pipeline.